Guidance maintained amid transition to newer growth avenues
29/10/26 -"The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s sales, the addition of Ophthalmology (with 2025 ..."
Pages
47
Language
English
Published on
29/10/26
You may also be interested by these reports :
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...
28/10/26
The Q3 profitability exceeded expectations, though sales came in line with consensus. The strong showing in ‘Specialty medicines’ made up for the ...
28/10/26
The Q3 sales missed consensus because of near-term biosimilar supply constraints, pricing pressure in Germany and lower prices for penicillin APIs – ...